The therapy Sarclisa (isatuximab) extended survival by nearly seven months in relapsed/refractory multiple myeloma patients also given Pomalyst (pomalidomide) and dexamethasone as standard treatment, according to updated three-year data from the ICARIA-MM Phase 3 trial. The data, “Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study,” were published in The Lancet Oncology. Sarclisa is an antibody-based therapy…
You must be logged in to read/download the full post.
The post Sarclisa Extends Survival in RRMM, Long-term Phase 3 Trial Data Shows appeared first on BioNewsFeeds.